Celldex Therapeutics (CLDX) Change in Receivables (2010 - 2026)

Celldex Therapeutics' Change in Receivables history runs 17 years deep, the most recent figure standing at -$1.8 million for Q1 2026.

• In Q1 2026, Change in Receivables fell 590.38% year-over-year to -$1.8 million; the TTM figure through Mar 2026 stood at -$834000.0 (up 48.1% YoY), while the FY2025 annual figure was $1.3 million, up 168.21% from the prior year.
• Change in Receivables was -$1.8 million for Q1 2026 at Celldex Therapeutics, down from $1.9 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $2.4 million in Q4 2023 to a low of -$1.8 million in Q1 2026.
• Historically, Change in Receivables has averaged $3625.0 across 5 years, with a median of $57000.0 in 2022.
• Biggest YoY gain for Change in Receivables was 1403.8% in 2023; the steepest drop was 719.18% in 2023.
• A 5-year view of Change in Receivables shows it stood at $158000.0 in 2022, then jumped by 1403.8% to $2.4 million in 2023, then plunged by 106.4% to -$152000.0 in 2024, then jumped by 1366.45% to $1.9 million in 2025, then plunged by 192.73% to -$1.8 million in 2026.
• The last three Change in Receivables figures came in at -$1.8 million (Q1 2026), $1.9 million (Q4 2025), and -$974000.0 (Q2 2025), per Business Quant data.